Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus QUINALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus QUINALAN.
NORPACE vs QUINALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)